Samuel G. Cockey

Samuel G. Cockey

Auto-generated profile, based on publicly available information

Samuel G. Cockey

University of South Florida Morsani College of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JLJulie Li
Julie Li
CRChristopher B Ryder
Christopher B Ryder
HZHailing Zhang
Hailing Zhang
SCSamuel G. Cockey
Samuel G. Cockey
EHElizabeth Hyjek
Elizabeth Hyjek
JSJinming Song
Jinming Song
Mast cell disorders range from benign proliferations to systemic diseases that cause anaphylaxis and other diverse symptoms to mast cell neoplasms with varied clinical outcomes. Mastocytosis is the pathologic process of the accumulation of abnormal mast cells in different organs, mostly driven by KIT mutations, and can present as cutaneous mastocytosis, systemic mastocytosis (SM), and mast cell sarcoma. The WHO 5th edition classification divides systemic mastocytosis into bone marrow mastocytosis, indolent systemic mastocytosis, smoldering systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. The new ICC classifies SM slightly differently. The diagnosis of SM requires the integration of bone marrow morphologic, immunophenotypic, and molecular findings, as well as clinical signs and symptoms. Moreover, understanding the wide range of clinical presentations for patients with mast cell disorders is necessary for accurate and timely diagnosis. This review provides an updated overview of mast cell disorders, with a special emphasis on SM, including the latest approaches to diagnosis, prognostic stratification, and management of this rare disease.

19 March 2021 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
SCSamuel G. Cockey
Samuel G. Cockey
KMKaren N. McFarland
Karen N. McFarland
EKEmily J. Koller
Emily J. Koller
MBMieu M. T. Brooks
Mieu M. T. Brooks
ECElsa Gonzalez De La Cruz
Elsa Gonzalez De La Cruz
PCParamita Chakrabarty
Paramita Chakrabarty
Parkinson’s disease (PD) and related synucleinopathies are characterized by chronic neuroinflammation leading to the premise that anti-inflammatory therapies could ameliorate synucleinopathy and associated sequelae. To test this idea, we used recombinant adeno-associated viruses (AAV) to express the anti-inflammatory cytokine, Interleukin (Il)-10, in Line M83 transgenic mice that expresses the PD-associated A53T mutant human α-synuclein (αSyn). Contrary to our expectations, we observed that intraspinal Il-10 expression initiated at birth upregulated microgliosis and led to early death in homozygous M83+/+ mice. We further observed that Il-10 preconditioning led to reduced lifespan in the hemizygous M83+/− mice injected with preformed αSyn aggregates in hindlimb muscles. To determine the mechanistic basis for these adverse effects, we took advantage of the I87A variant Il-10 (vIl-10) that has predominantly immunosuppressive properties. Sustained intraspinal expression of vIl-10 in preformed αSyn-aggregate seeded M83+/− mice resulted in earlier death, accelerated αSyn pathology, pronounced microgliosis, and increased apoptosis compared to control mice. AAV-vIl-10 expression robustly induced p62 and neuronal LC3B accumulation in these mice, indicating that Il-10 signaling mediated preconditioning of the neuraxis can potentially exacerbate αSyn accumulation through autophagy dysfunction in the neurons. Together, our data demonstrate unexpected adverse effects of both Il-10 and its immunosuppressive variant, vIl-10, in a mouse model of PD, highlighting the pleiotropic functions of immune mediators and their complex role in non-cell autonomous signaling in neurodegenerative proteinopathies.

3 January 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NGNidhi Ghildayal
Nidhi Ghildayal
JHJingyao Hong
Jingyao Hong
YLYi Liu
Yi Liu
YLYiting Li
Yiting Li
SCSamuel G. Cockey
Samuel G. Cockey
MMMara McAdams-DeMarco
Mara McAdams-DeMarco
Key Points: In frail kidney transplant (KT) candidates with obesity, unintentional weight loss preceding KT evaluation is associated with lower chance of listing. In frail candidates with obesity, both unintentional and intentional weight loss is associated with higher waitlist mortality. Results suggest that in frail candidates with obesity, careful supervision of weight loss prior to KT should be considered, emphasizing strategies to preserve muscle mass and function. Background: Unintentional weight loss, a hallmark of frailty, predicts worse post–kidney transplantation (KT) outcomes. However, weight loss in candidates with obesity is often recommended to enhance transplant eligibility. We tested whether pre-evaluation weight change is associated with listing/waitlist mortality, considering intentionality and frailty. Methods: We leveraged data on body mass index, weight loss intentionality (1 year before evaluation and at evaluation), and frailty (four-component Physical Frailty Phenotype at evaluation) for 1361 candidates (895 listed) with obesity (body mass index ≥30 kg/m 2 ) enrolled in a prospective multicenter cohort study. We estimated the association between pre-evaluation weight change (stable, gain, unintentional/intentional loss) with chance of listing/waitlist mortality using Cox proportional hazards/competing-risks models. Results: Among candidates with obesity, 48% had stable weight, 17% had weight gain, 16% had unintentional weight loss, and 20% had intentional weight loss over the year before evaluation. Among frail candidates with obesity, stable weight was associated with a 27% lower chance of listing (adjusted hazard ratio [aHR], 0.73; 95% confidence intervals [CI], 0.55 to 0.96), weight gain with a 47% lower chance of listing (aHR, 0.53; 95% CI, 0.34 to 0.80), and unintentional weight loss with a 48% lower chance of listing (aHR, 0.52; 95% CI, 0.32 to 0.84) compared with nonfrail candidates with stable weight. However, in frail candidates with obesity, intentional weight loss was not associated with a significantly lower chance of listing compared with nonfrail candidates with stable weight. In addition, among frail candidates with obesity, stable weight (adjusted subhazard ratio [aSHR], 1.72; 95% CI, 1.01 to 2.90), unintentional weight loss (aSHR, 2.78; 95% CI, 1.23 to 6.27), and intentional weight loss (aSHR, 2.26; 95% CI, 1.05 to 4.85) were associated with higher waitlist mortality compared with nonfrail candidates with stable weight. Among nonfrail candidates, no associations were observed for weight change and frailty status with either chance of listing or waitlist mortality. Conclusions: Among frail candidates with obesity, unintentional pre-KT weight loss is associated with a lower chance of listing; however, any weight loss is associated with higher waitlist mortality. Our findings suggest that frail candidates with obesity may benefit from clinician supervision of pre-KT weight loss.

29 November 2024 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SCSamuel G. Cockey
Samuel G. Cockey
HZHailing Zhang
Hailing Zhang
MHMohammed Hussaini
Mohammed Hussaini
LZLing Zhang
Ling Zhang
LMLynn Moscinski
Lynn Moscinski
JSJinming Song
Jinming Song
The mutations in SRSF2 and TET2 genes are frequently present in various myeloid neoplasms. The potential impact of SRSF2/TET2 co-mutations on patient survival is incompletely understood. We identified 412 patients with SRSF2/TET2 co-mutations from our NextGen sequencing database of around 8000 patients and reported likely the largest cohort study. Our study demonstrated the presence of these co-mutations in a spectrum of myeloid neoplasms, which show different genetic and molecular characteristics. Most of the patients with these co-mutations had normal karyotype. Interestingly, our study provided insights into the prevalence of additional mutations such as ASXL1, RUNX1, and KRAS with this co-mutation and their potential impact on patients' prognosis. We found that ASXL1, RUNX1, and KRAS can negatively impact these patients' survival with different impacts in different morphological diagnosis categories, suggesting a complex interaction between these genes. This study underscores the need for personalized approaches in the treatment of myeloid neoplasms.

7 December 2023 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
SCSamuel G. Cockey
Samuel G. Cockey
HXHongzhi Xu
Hongzhi Xu
MAMohammed AL-JUMAYLI
Mohammed AL-JUMAYLI
Background: Cancer antigen 15-3 is a protein that clinicians commonly measure to monitor outcomes and response to treatment in patients with breast cancer. However, cancer antigen 15-3 can also be elevated in other, benign and malignant conditions. Case presentation: A 73-year-old White woman with history of breast cancer presented to her primary care physician with right hip pain, and laboratory testing revealed elevated cancer antigen 15-3. Further workup with radiographic imaging revealed a large mass in her right kidney. The renal mass was subsequently removed, and the cancer antigen 15-3 level returned to normal. Conclusions: Elevation of cancer antigen 15-3 owing to causes other than breast cancer recurrence can be a potential diagnostic pitfall during a patient’s follow-up. It is important for clinicians to be aware of the limitations of cancer markers and to utilize a combination of diagnostic tests for patient evaluation.

12 August 2026 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MMMichael Sean Martin
Michael Sean Martin
SCSamuel G. Cockey
Samuel G. Cockey
VJVeena Jajoo
Veena Jajoo
MSMac Shebes
Mac Shebes
HZHailing Zhang
Hailing Zhang
JSJinming Song
Jinming Song
Myeloid neoplasms are a heterogeneous group of disorders originating from aberrant mutations of hematopoietic stem cells in the bone marrow Arber et al. [1]. Among these are myelodysplastic syndrom...